Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Halozyme Therapeutics (NASDAQ: HALO) has announced its participation in the upcoming TD Cowen 45th Annual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Halozyme Therapeutics (NASDAQ: HALO) has announced its participation in the upcoming TD Cowen 45th Annual Healthcare Conference. Dr. Helen Torley, president and chief executive officer, will deliver a presentation on Wednesday, March 5 at 8:50am PT / 11:50am ET.
The company will provide a live audio webcast of the presentation through their Investor Relations website section. The webcast recording will remain accessible for 90 days following the conference, allowing investors and interested parties to review the presentation at their convenience.
Details
News Market Reaction – HALO
The recorded move for HALO in the trading session of this news was -0.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET.
A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-td-cowen-45th-annual-healthcare-conference-302385786.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.